Heron Therapeutics (HRTX) CEO gets 13,797 shares from RSU vesting

Rhea-AI Filing Summary

Heron Therapeutics, Inc. Chief Executive Officer Craig A. Collard reported an RSU vesting and share acquisition on 01/19/2026. A total of 13,797 restricted stock units were converted at an exercise price of $0 into 13,797 shares of common stock, reflecting previously granted equity compensation rather than an open-market purchase.

Each restricted stock unit represents a contingent right to receive one share of common stock, and these RSUs vest in 16 equal quarterly installments beginning one quarter after the 01/19/2024 grant date. Following this transaction, Collard directly held 110,375 restricted stock units and 536,921 shares of common stock.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Collard Craig A

(Last) (First) (Middle)

100 REGENCY FOREST DRIVE

SUITE 300

(Street)

CARY NC 27518

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
HERON THERAPEUTICS, INC. /DE/ [ HRTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/19/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/19/2026		M		13,797	A	(1)	536,921	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	$0	01/19/2026		M			13,797	(2)	(2)	Common Stock	13,797	$0	110,375	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of common stock.

2. The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (01/19/2024).

	/s/Kathryn Lester Attorney-in-fact for Craig Collard	01/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did HRTX CEO Craig Collard report?

Craig A. Collard, Chief Executive Officer and Director of Heron Therapeutics, Inc. (HRTX), reported the vesting of 13,797 restricted stock units and their conversion into 13,797 shares of common stock on 01/19/2026 under transaction code M.

Was the HRTX CEO’s Form 4 transaction a stock sale or an RSU vesting?

The Form 4 for HRTX reflects an RSU vesting and conversion, not a sale. 13,797 restricted stock units were converted into 13,797 shares of common stock at a price of $0, consistent with equity award settlement.

How many HRTX shares does CEO Craig Collard hold after this Form 4 transaction?

After the reported transaction, Craig A. Collard beneficially owned 536,921 shares of common stock of Heron Therapeutics, Inc., held directly, according to the filing.

How many restricted stock units does the HRTX CEO still hold after the vesting?

Following the 01/19/2026 vesting event, Craig A. Collard held 110,375 restricted stock units, each representing a contingent right to receive one share of Heron Therapeutics, Inc. common stock.

How do the HRTX CEO’s restricted stock units vest over time?

The filing states that the restricted stock units granted on 01/19/2024 vest in 16 equal quarterly installments, beginning one quarter after the grant date, providing a structured, long-term equity vesting schedule.

What does transaction code M mean in the HRTX CEO’s Form 4?

In this Form 4 for Heron Therapeutics, Inc. (HRTX), transaction code M indicates the exercise or conversion of a derivative security. Here it reflects the conversion of 13,797 restricted stock units into common stock.